• BioAge Labs published an R&D Day presentation highlighting Phase 1 results for lead program BGE-102, an oral brain-penetrant NLRP3 inhibitor positioned for cardiometabolic disease.
• Presentation flagged 86% hsCRP reduction in obese subjects, with 87-93% achieving normalized hsCRP below 2 mg/L.
• Program profile included 24-hour IL-1β suppression of at least 90% at 60 mg once daily, with CNS penetration reported at about 0.7 Kp,uu CSF at 120 mg multiple ascending dose on day 14.
• Update outlined upcoming proof-of-concept readouts for cardiovascular risk in H2 2026, with diabetic macular edema proof-of-concept targeted for mid-2027.
• Company also highlighted an APJ agonist obesity program, with IND submission targeted for year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.